Catheter, Percutaneous(DQY)

経皮的カテーテル この日本語名は AI が生成した参考訳です。正式名称は英語の原名です。

米国回収

619 件

直近 2026.06.24

510(k)

896 件

PMA

0 件

不具合報告

42,268 件

分類情報

Product Code DQY
デバイス名 Catheter, Percutaneous

経皮的カテーテル この日本語名は AI が生成した参考訳です。正式名称は英語の原名です。

デバイスクラス クラス II
21 CFR 規制番号 870.1250
審査区分 510(k)(市販前届出)
医療専門分野 循環器
定義 -
フラグ
該当なし
AI分析

本品は、血管内へ経皮的に挿入して使用するカテーテルです。米国では21 CFR 870.1250に基づきクラスIIに分類され、市販前届出(510(k))により既存の同等品との実質的同等性を示すことで市販が可能となる審査区分に位置づけられています。

米国市場での動向

本製品区分では510(k)が累計約900件、参入企業は279社、直近5年では約90件の届出があり、PMAの実績は確認されていません。不具合報告は累計約42,000件で、うち不具合(Malfunction)が約31,000件と中心を占め、死亡が910件、傷害が約9,500件報告されており、主な問題としてMaterial Rupture/BreakやMaterial Twisted/Bentが挙げられています。回収は累計約620件で、クラスIが220件、クラスIIが約150件、クラスIIIが4件含まれており、直近5年では約40件、最新の回収は2026年4月に開始されています。

この分析は公開データ(openFDA・JMDN 対応情報)をもとに AI が生成した参考情報です。市場データは2026年11月時点の集計に基づきます。

関連 product code

同じ 21 CFR 870.1250 に分類される product code(12 件)

No.product code機器名クラス専門分野510(k)PMA不具合回収
1LIT

Catheter, Angioplasty, Peripheral, Transluminal

経皮的末梢血管形成術用カテーテル

II循環器405336,26132 件
2NRY

Catheter, Thrombus Retriever

血栓除去用カテーテル

II循環器117—8,72625 件
3QJP

Catheter, Percutaneous, Neurovasculature

経皮的神経血管系カテーテル

II循環器103—1,9247 件
4PDU

Catheter For Crossing Total Occlusions

完全閉塞病変貫通用カテーテル

II循環器58—1,4087 件
5PNO

Catheter, Percutaneous, Cutting/Scoring

経皮的カッティング/スコアリングカテーテル

II循環器47—2,1933 件
6NTE

Temporary Carotid Catheter For Embolic Capture

頸動脈用一時的塞栓捕捉カテーテル

II循環器36—5,38728 件
7NFA

Temporary Coronary Saphenous Vein Bypass Graft For Embolic Protection

塞栓防止用一時的冠動脈静脈バイパスグラフト

II循環器22—2,0454 件
8PPN

Percutaneous Catheter, Ultrasound

経皮的超音波バルーン拡張カテーテル

II循環器14—2571 件
9NVM

Catheter, Angioplasty, Peripheral, Transluminal, Dual-Balloon

経皮経管的末梢血管形成術用ダブルバルーンカテーテル

II循環器5—262 件
10OMZ

Pulmonary (Pulmonic) Valvuloplasty Catheters/Percutaneous Valvuloplasty Catheter

経皮的肺動脈弁形成術用カテーテル

II循環器5—22—
11NMM

Catheter, Angioplasty, Peripheral, Transluminal, Reprocessed

II循環器————
12OFK

Percutaneous Atrial Catheter Kit

経皮的心房カテーテルキット

II循環器——732 件

機器名の日本語訳は AI により自動生成したものです。正確には英語原文をご確認ください。

類似の国内医療機器(自動推定)

FDA デバイス分類と JMDN 英語名の名称・定義文の類似度から機械的に推定した候補です。日米の当局が定めた公的な対応関係ではなく、参考情報としてご覧ください。

No.類別一般的名称品目数企業数年間総出荷額成長率平均価格国産比率
1医療用嘴管及び体液誘導管経皮泌尿器用カテーテルクラスⅡ20125.34 億円/年-5.0% 2.22 万円/個0.0%
2医薬品注入器皮下用ポート及びカテーテルクラスⅢ430 億円/年-100.0% 2.8 万円/個0.0%
3医療用嘴管及び体液誘導管経皮洗浄向け泌尿器用カテーテルクラスⅡ——————
4医療用嘴管及び体液誘導管経皮排液向け腹膜用カテーテルクラスⅡ——————
5医療用嘴管及び体液誘導管冠動脈灌流用カテーテルクラスⅣ13————

FDA のデバイスクラスは 3 段階(クラス I〜III)、日本の医療機器は 4 段階(クラス I〜IV)で分類されており、 1 対 1 では対応しません。 リスク区分の考え方が異なるため、参考情報としてご利用ください。

米国での回収・承認・不具合報告

無料会員 1,000名 突破

回収・承認・不具合報告の明細の閲覧は会員限定です

無料で会員登録する
回収番号クラス回収開始日企業理由ステータス
Z-2377-2026 DQYクラス I(最重篤)2026.04.21ARROW INTERNATIONAL, LLC

Lidocaine, Bupivacaine, and 0.9% sodium chloride, the subject of a supplier recall, were included into kits and sets. The supplier was found to have quality issues and limited reports of drug ineffectiveness, and if sterility of a water-based injectable product is compromised this could lead to serious or life-threatening injuries.

対応中
Z-0188-2026 DQYクラス I(最重篤)2025.09.25BALT USA, LLC

Due to an identified manufacturing defect involving coating material lifting within the catheter's distal inner diameter/lumen.

対応中
Z-2436-2025 DQYクラス I(最重篤)2025.07.29Boston Scientific Corporation

Boston Scientific has identified a higher likelihood of air embolism events when procedures are performed without positive pressure-controlled ventilation. According to published literature and clinical data, in percutaneous procedures requiring transseptal access to the left atrium when conscious or deep sedation is used, patients have an approximately three-times higher risk (U.S. study) of negative left atrium pressure and air ingress. This risk is especially prevalent in patients with pre-existing low left atrial pressure, hypovolemia, and partial upper airway collapse.

対応中
Z-2435-2025 DQYクラス I(最重篤)2025.07.29Boston Scientific Corporation

Boston Scientific has identified a higher likelihood of air embolism events when procedures are performed without positive pressure-controlled ventilation. According to published literature and clinical data, in percutaneous procedures requiring transseptal access to the left atrium when conscious or deep sedation is used, patients have an approximately three-times higher risk (U.S. study) of negative left atrium pressure and air ingress. This risk is especially prevalent in patients with pre-existing low left atrial pressure, hypovolemia, and partial upper airway collapse.

対応中
Z-2434-2025 DQYクラス I(最重篤)2025.07.29Boston Scientific Corporation

Boston Scientific has identified a higher likelihood of air embolism events when procedures are performed without positive pressure-controlled ventilation. According to published literature and clinical data, in percutaneous procedures requiring transseptal access to the left atrium when conscious or deep sedation is used, patients have an approximately three-times higher risk (U.S. study) of negative left atrium pressure and air ingress. This risk is especially prevalent in patients with pre-existing low left atrial pressure, hypovolemia, and partial upper airway collapse.

対応中
Z-2433-2025 DQYクラス I(最重篤)2025.07.29Boston Scientific Corporation

Boston Scientific has identified a higher likelihood of air embolism events when procedures are performed without positive pressure-controlled ventilation. According to published literature and clinical data, in percutaneous procedures requiring transseptal access to the left atrium when conscious or deep sedation is used, patients have an approximately three-times higher risk (U.S. study) of negative left atrium pressure and air ingress. This risk is especially prevalent in patients with pre-existing low left atrial pressure, hypovolemia, and partial upper airway collapse.

対応中
Z-2432-2025 DQYクラス I(最重篤)2025.07.29Boston Scientific Corporation

Boston Scientific has identified a higher likelihood of air embolism events when procedures are performed without positive pressure-controlled ventilation. According to published literature and clinical data, in percutaneous procedures requiring transseptal access to the left atrium when conscious or deep sedation is used, patients have an approximately three-times higher risk (U.S. study) of negative left atrium pressure and air ingress. This risk is especially prevalent in patients with pre-existing low left atrial pressure, hypovolemia, and partial upper airway collapse.

対応中
Z-2431-2025 DQYクラス I(最重篤)2025.07.29Boston Scientific Corporation

Boston Scientific has identified a higher likelihood of air embolism events when procedures are performed without positive pressure-controlled ventilation. According to published literature and clinical data, in percutaneous procedures requiring transseptal access to the left atrium when conscious or deep sedation is used, patients have an approximately three-times higher risk (U.S. study) of negative left atrium pressure and air ingress. This risk is especially prevalent in patients with pre-existing low left atrial pressure, hypovolemia, and partial upper airway collapse.

対応中
Z-2430-2025 DQYクラス I(最重篤)2025.07.29Boston Scientific Corporation

Boston Scientific has identified a higher likelihood of air embolism events when procedures are performed without positive pressure-controlled ventilation. According to published literature and clinical data, in percutaneous procedures requiring transseptal access to the left atrium when conscious or deep sedation is used, patients have an approximately three-times higher risk (U.S. study) of negative left atrium pressure and air ingress. This risk is especially prevalent in patients with pre-existing low left atrial pressure, hypovolemia, and partial upper airway collapse.

対応中
Z-2429-2025 DQYクラス I(最重篤)2025.07.29Boston Scientific Corporation

Boston Scientific has identified a higher likelihood of air embolism events when procedures are performed without positive pressure-controlled ventilation. According to published literature and clinical data, in percutaneous procedures requiring transseptal access to the left atrium when conscious or deep sedation is used, patients have an approximately three-times higher risk (U.S. study) of negative left atrium pressure and air ingress. This risk is especially prevalent in patients with pre-existing low left atrial pressure, hypovolemia, and partial upper airway collapse.

対応中
Z-2428-2025 DQYクラス I(最重篤)2025.07.29Boston Scientific Corporation

Boston Scientific has identified a higher likelihood of air embolism events when procedures are performed without positive pressure-controlled ventilation. According to published literature and clinical data, in percutaneous procedures requiring transseptal access to the left atrium when conscious or deep sedation is used, patients have an approximately three-times higher risk (U.S. study) of negative left atrium pressure and air ingress. This risk is especially prevalent in patients with pre-existing low left atrial pressure, hypovolemia, and partial upper airway collapse.

対応中
Z-2427-2025 DQYクラス I(最重篤)2025.07.29Boston Scientific Corporation

Boston Scientific has identified a higher likelihood of air embolism events when procedures are performed without positive pressure-controlled ventilation. According to published literature and clinical data, in percutaneous procedures requiring transseptal access to the left atrium when conscious or deep sedation is used, patients have an approximately three-times higher risk (U.S. study) of negative left atrium pressure and air ingress. This risk is especially prevalent in patients with pre-existing low left atrial pressure, hypovolemia, and partial upper airway collapse.

対応中
Z-2426-2025 DQYクラス I(最重篤)2025.07.29Boston Scientific Corporation

Boston Scientific has identified a higher likelihood of air embolism events when procedures are performed without positive pressure-controlled ventilation. According to published literature and clinical data, in percutaneous procedures requiring transseptal access to the left atrium when conscious or deep sedation is used, patients have an approximately three-times higher risk (U.S. study) of negative left atrium pressure and air ingress. This risk is especially prevalent in patients with pre-existing low left atrial pressure, hypovolemia, and partial upper airway collapse.

対応中
Z-1644-2025 DQYクラス II2025.03.17Abbott

Device may have a small breach in the proximal end of the shaft under the strain relief of the delivery system. Breach is not visibly detectable and may lead to prolonged procedure, blood loss, or air ingress with potential for air embolism.

対応中
Z-1643-2025 DQYクラス II2025.03.17Abbott

Device may have a small breach in the proximal end of the shaft under the strain relief of the delivery system. Breach is not visibly detectable and may lead to prolonged procedure, blood loss, or air ingress with potential for air embolism.

対応中
Z-1330-2025 DQYクラス II2025.02.07Cordis US Corp

Catheter manufactured at the incorrect length.

対応中
Z-0990-2025 DQYクラス II2024.12.02MICROVENTION INC.

Sterility assurance; microcatheter inner packaging may contain incomplete seal.

対応中
Z-1908-2024 DQYクラス II2024.04.23Stryker Neurovascular

Neurovascular devices did not meet the minimum sample size required for endotoxin testing during manufacturing processes and are out of compliance with the AAMI ST72 standard, so these devices may exceed the acceptable limits of endotoxin levels; high levels of endotoxins may increase the risk of fever, shock and aseptic meningitis.

対応中
Z-1907-2024 DQYクラス II2024.04.23Stryker Neurovascular

Neurovascular devices did not meet the minimum sample size required for endotoxin testing during manufacturing processes and are out of compliance with the AAMI ST72 standard, so these devices may exceed the acceptable limits of endotoxin levels; high levels of endotoxins may increase the risk of fever, shock and aseptic meningitis.

対応中
Z-1740-2024 DQYクラス II2024.04.03Stryker Neurovascular

Stryker Neurovascular is recalling their DAC- Distal Access Catheter -038 136cm, a Distal Access Catheter by removal. The reason for the recall is: the DAC Lot #0000486382 was released with out-of-specification endotoxin results.

対応中

510(k)(市販前届出)

全 896 件
No.番号機器名申請者決定日種別概要
1K262817 CrossFAST Integrated Microcatheter Advanced Delivery SystemVantis Vascular, Inc.2026.09.18特別(Special) PDF
2K260559 NHanceITIMDS Operation B.V.2026.08.14通常(Traditional) PDF
3K262392 APRO 35 Swift CatheterAlembic, LLC2026.08.12特別(Special) PDF
4K262240 SSPC NXT Delivery CatheterCenterPoint Systems, LLC2026.07.29特別(Special) PDF
5K261766 CPS Locator 3D Plus Delivery CatheterCenterPoint Systems, LLC2026.07.29特別(Special) PDF
6K261825 Amplatzer TorqVue LP Delivery System; Amplatzer TorqVue LP CatheterAbbott2026.07.02特別(Special) PDF
7K261631 Amplatzer TorqVue Exchange SystemAbbott Medical2026.06.17特別(Special) PDF
8K260289 Perfect-O Ostial Positioning CatheterBalosmark, Inc.2026.06.05通常(Traditional) PDF
9K260993 Amplatzer TorqVue Delivery SystemAbbott2026.04.24特別(Special) PDF
10K253361 Teleport Glide MicrocatheterOrbusNeich Medical (Shenzhen) Co., Ltd.2026.04.10通常(Traditional) PDF
11K260499 Amplatzer™ Trevisio™ Intravascular Delivery System; 9-ATV06F45/609-ATV07F45/609-ATV07F45/809-ATV08F45/609-ATV08F45/809-ATV09F45/809-ATV10F45/809-ATV12F45/80ABBOTT MEDICAL2026.03.13特別(Special) PDF
12K253409 C320LBB Delivery System (C320LBBS45), C320LBB Delivery System (C320LBBS48), C320LBB Delivery System (C320LBBL45), C320LBB Delivery System (C320LBBL48)Medtronic, Inc.2025.12.19通常(Traditional) PDF
13K252417 Amplatzer Piccolo™ Delivery System (9-PDS-04F-045)ABBOTT MEDICAL2025.12.17通常(Traditional) PDF
14K252390 Telescope Guide Extension CatheterMedtronic, Ireland2025.10.29通常(Traditional) PDF
15K251277 CoraForce Microcatheter, CoraFlex MicrocatheterReflow Medical, Inc.2025.08.22特別(Special) PDF
16K250147 CPS Locator 3D Delivery CatheterCenterpoint Systems2025.08.22通常(Traditional) PDF
17K250972 Primum Hydrophilic Guiding CatheterPendracare2025.06.29通常(Traditional) PDF
18K250828 CPS Locator 3D Plus Delivery CatheterCenterPoint Systems, LLC2025.06.27特別(Special) PDF
19K243184 SAT CenterFlow Molding Balloon Catheter (IN20-00313)Strait Access Technologies Holdings2025.06.25通常(Traditional) PDF
20K250492 FlexiGo 3D Delivery CatheterCenterPoint Systems, LLC2025.06.18特別(Special) PDF

出典の openFDA は各 510(k) の主要(primary)product code のみを収録しているため、副次コードを含む FDA 公式データベースの検索結果とは件数が異なる場合があります。 FDA 510(k) データベースで確認

PMA(市販前承認)

この product code の PMA 情報はありません。

不具合報告(MAUDE)トレンド

米国不具合報告検索で詳しく見る

出典: openFDA(U.S. FDA) のデータをそのまま掲載しています。内容の正確性・最新性は保証されません。FDA が本サイトの内容を承認・保証するものではありません。

報告の存在は、機器と事象の因果関係を意味しません。報告件数を機器間の不具合発生率の比較に用いることはできません。

各データセット(510(k)・PMA・MAUDE・回収・Warning Letter)の解説は 米国FDA情報の概要 を参照してください。

不具合報告データを読み込み中...

出典: openFDA(U.S. FDA) のデータをそのまま掲載しています。内容の正確性・最新性は保証されません。FDA が本サイトの内容を承認・保証するものではありません。

取得日: 2026.11.16

各データセット(510(k)・PMA・MAUDE・回収・Warning Letter)の解説は 米国FDA情報の概要 を参照してください。